M&A: Citius Pharmaceuticals, Inc.

Form Type: 10-K

Filing Date: 2024-12-27

Corporate Action: Merger

Type: Update

Accession Number: 000121390024113149

Comments: Citius Pharmaceuticals, Inc. completed a significant merger with Citius Oncology, Inc. on August 12, 2024, which involved a reverse merger where Citius Oncology became a publicly traded entity and a majority-owned subsidiary of Citius Pharma. This strategic move aimed to leverage Citius Oncology's FDA-approved product, LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for treating persistent or recurrent cutaneous T-cell lymphoma. The merger is viewed as a means to enhance the financial positioning and operational capabilities of Citius Pharma. Additionally, this annual filing outlines the details of the company's business operations, risk factors including the need for ongoing financing and potential regulatory challenges, and various proprietary products in development. The report further emphasizes the company's focus on addressing unmet medical needs using innovative applications, including their late-stage candidates Mino-Lok and Halo-Lido. Key financial metrics such as a market valuation of approximately $131.67 million and 7,727,243 shares outstanding as of December 18, 2024, are noted.

Document Link: View Document